利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.028 秒)

    Acarbose methods and formulations for treating chronic constipation
    21.
    发明申请
    Acarbose methods and formulations for treating chronic constipation 审中-公开
    用于治疗慢性便秘的阿卡波糖方法和制剂

    公开(公告)号：US20060229261A1

    公开(公告)日：2006-10-12

    申请号：US11392708

    申请日：2006-03-30

    申请人： John Devane

    发明人： John Devane

    IPC分类号： A61K31/70 ,  A61K31/155

    CPC分类号： A61K31/715 ,  A61K31/155 ,  A61K31/70

    摘要： The present invention is directed to a method for treating chronic constipation in a subject in need of such treatment comprising administering to the subject a dosage formulation comprising a therapeutically effective amount of acarbose, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable ingredient to control the release of the acarbose, wherein following administration, the dosage formulation releases the acarbose distal to the gastrointestinal sites at which acarbose is absorbed.

    摘要翻译： 本发明涉及一种用于治疗需要这种治疗的受试者的慢性便秘的方法，其包括向受试者施用包含治疗有效量的阿卡波糖或其药学上可接受的盐的剂型，和至少一种药学上可接受的成分 以控制阿卡波糖的释放，其中在给药后，剂量制剂将阿卡波糖释放到吸收阿卡波糖的胃肠部位的远端。

    Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
    23.
    发明申请
    Pharmaceutical formulations for carrier-mediated transport statins and uses thereof 有权
    用于载体介导的运输他汀类药物的制剂及其用途

    公开(公告)号：US20050119331A1

    公开(公告)日：2005-06-02

    申请号：US10967167

    申请日：2004-10-19

    申请人： Jackie Butler ,  John Devane ,  Paul Stark

    发明人： Jackie Butler ,  John Devane ,  Paul Stark

    IPC分类号： A61K9/20 ,  A61K9/28 ,  A61K31/40 ,  A61K31/505 ,  A61K31/401 ,  A61K31/225 ,  A61K31/366

    CPC分类号： A61K31/505 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/284 ,  A61K9/2846 ,  A61K31/40 ,  C07D207/34

    摘要： The present invention relates to formulations comprising therapeutically effective amounts of at least one acid-stable, carrier-mediated transport statin, at least one poorly water-soluble, carrier-mediated transport statin, or at least one large molecular weight, carrier-mediated transport statin, such as atorvastatin and rosuvastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to exhibit a controlled-release of a therapeutic amount of the statin in the small intestine, thereby limiting systemic exposure of the statin and maximizing liver-specific absorption of the drug. The formulations and methods of the present invention are particularly useful for treating and/or preventing conditions that are benefited by decreasing levels of lipids and/or cholesterol in the body.

    摘要翻译： 本发明涉及包含治疗有效量的至少一种酸稳定的载体介导的转运他汀类药物，至少一种难溶于水的载体介导的转运他汀类药物或至少一种大分子量的载体介导的转运体 他汀类药物，如阿托伐他汀和罗苏伐他汀，或其药学上可接受的盐及其使用方法。 本发明的制剂和方法设计用于在小肠中显示治疗量的他汀类药物的受控释放，从而限制他汀类药物的全身暴露并使药物的肝脏特异性吸收最大化。 本发明的制剂和方法特别可用于治疗和/或预防通过降低体内脂质和/或胆固醇水平而受益的病症。

    Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists
    24.
    发明申请
    Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists 审中-公开
    用GABAB激动剂治疗胃轻瘫和非溃疡性消化不良

    公开(公告)号：US20050090554A1

    公开(公告)日：2005-04-28

    申请号：US10935176

    申请日：2004-09-08

    申请人： John Devane ,  Jackie Butler

    发明人： John Devane ,  Jackie Butler

    IPC分类号： A61K9/00 ,  A61K9/28 ,  A61K9/70 ,  A61K31/195 ,  A61K31/198

    CPC分类号： A61K31/195 ,  A61K9/0004 ,  A61K9/2846 ,  A61K9/7023

    摘要： The present invention relates to formulations comprising a therapeutically effective amount of baclofen or (R)-baclofen, or pharmaceutically acceptable salts thereof, and methods of their use. The present formulations and methods are designed to release a therapeutic amount of baclofen in a manner that maximizes its therapeutic effect. The methods and formulations are especially suitable for treating gastroparesis and nonulcer dyspepsia.

    摘要翻译： 本发明涉及包含治疗有效量的巴氯芬或（R） - 巴氯芬或其药学上可接受的盐的制剂及其使用方法。 本发明的制剂和方法被设计为以最大化其治疗效果的方式释放治疗量的巴氯芬。 方法和制剂特别适用于治疗胃轻瘫和非溃疡性消化不良。

    Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
    26.
    发明授权
    Pharmaceutical formulations for carrier-mediated transport statins and uses thereof 有权
    用于载体介导的运输他汀类药物的制剂及其用途

    公开(公告)号：US08987322B2

    公开(公告)日：2015-03-24

    申请号：US10967167

    申请日：2004-10-19

    申请人： Jackie Butler ,  John Devane ,  Paul Stark

    发明人： Jackie Butler ,  John Devane ,  Paul Stark

    IPC分类号： A61K31/40 ,  A61K9/28 ,  A61K9/20 ,  A61K31/505 ,  C07D207/34

    CPC分类号： A61K31/505 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/284 ,  A61K9/2846 ,  A61K31/40 ,  C07D207/34

    摘要： The present invention relates to formulations comprising therapeutically effective amounts of at least one acid-stable, carrier-mediated transport statin, at least one poorly water-soluble, carrier-mediated transport statin, or at least one large molecular weight, carrier-mediated transport statin, such as atorvastatin and rosuvastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to exhibit a controlled-release of a therapeutic amount of the statin in the small intestine, thereby limiting systemic exposure of the statin and maximizing liver-specific absorption of the drug. The formulations and methods of the present invention are particularly useful for treating and/or preventing conditions that are benefited by decreasing levels of lipids and/or cholesterol in the body.

    摘要翻译： 本发明涉及包含治疗有效量的至少一种酸稳定的载体介导的转运他汀类药物，至少一种难溶于水的载体介导的转运他汀类药物或至少一种大分子量的载体介导的转运体 他汀类药物，如阿托伐他汀和罗苏伐他汀，或其药学上可接受的盐及其使用方法。 本发明的制剂和方法设计用于在小肠中显示治疗量的他汀类药物的受控释放，从而限制他汀类药物的全身暴露并使药物的肝脏特异性吸收最大化。 本发明的制剂和方法特别可用于治疗和/或预防通过降低体内脂质和/或胆固醇水平而受益的病症。

    (R)-2-(3,4-DIMETHOXYPHENOL)-2-ISOPROPYL-6-AZAHEPTANITRIL FORMULAITONS, ANDTHE USE OF SUCH FORMULATIONS IN THE TREATMENT OF CONDITIONS MEDIATED BY THE SEROTONIN TRANSPORTER
    27.
    发明申请
    (R)-2-(3,4-DIMETHOXYPHENOL)-2-ISOPROPYL-6-AZAHEPTANITRIL FORMULAITONS, ANDTHE USE OF SUCH FORMULATIONS IN THE TREATMENT OF CONDITIONS MEDIATED BY THE SEROTONIN TRANSPORTER 审中-公开
    （R）-2-（3,4-二甲氧基苯酚）-2-异丙基-6-亚氨基吡啶类药物，以及此类制剂用于治疗丝氨酸转运蛋白介导的病症的方法

    公开(公告)号：US20110301245A1

    公开(公告)日：2011-12-08

    申请号：US12850329

    申请日：2010-08-04

    申请人： John DEVANE

    发明人： John DEVANE

    IPC分类号： A61K31/277 ,  A61P9/00 ,  A61P9/12

    CPC分类号： A61K31/277

    摘要： Methods comprising administering compositions comprising therapeutically effective amounts of the (R)-isomer of 2-(3,4-dimethoxyphenol)-2-isopropyl-6-azaheptanitril, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein the composition treats or prevents at least one condition having serotonin transporter activity in a subject in need thereof, and releases the (R)-isomer of 2-(3,4-dimethoxyphenol)-2-isopropyl-6-azaheptanitril, a derivative thereof, or a pharmaceutically acceptable salt thereof to exhibit an activity on the serotonin transporter.

    摘要翻译： 方法包括施用包含治疗有效量的2-（3,4-二甲氧基苯酚）-2-异丙基-6-氮杂庚基的（R） - 异构体，其衍生物或其药学上可接受的盐的组合物，其中组合物治疗或 在有需要的受试者中防止至少一种具有5-羟色胺转运蛋白活性的病症，并释放出2-（3,4-二甲氧基苯酚）-2-异丙基-6-氮杂庚基，其衍生物或其药学上可接受的（R） - 异构体 其可接受的盐在5-羟色胺转运蛋白上表现出活性。

    Formulations and Methods of Treating Inflammatory Bowel Disease
    28.
    发明申请
    Formulations and Methods of Treating Inflammatory Bowel Disease 有权
    治疗炎症性肠病的制剂和方法

    公开(公告)号：US20100278917A1

    公开(公告)日：2010-11-04

    申请号：US12797655

    申请日：2010-06-10

    申请人： John Devane ,  Jackie Butler

    发明人： John Devane ,  Jackie Butler

    IPC分类号： A61K9/10 ,  A61K31/606 ,  A61P1/00 ,  A61P1/04

    CPC分类号： A61K9/2059 ,  A61K9/2054 ,  A61K9/284 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2886 ,  A61K9/5078 ,  A61K31/606 ,  A61K31/655 ,  C07C245/08

    摘要： Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid to affected areas of the intestine. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.

    摘要翻译： 公开了治疗炎症性肠病的方法和制剂。 方法和制剂包括但不限于用于将有效浓度的4-氨基水杨酸和/或5-氨基水杨酸递送至肠的受影响区域的方法和制剂。 方法和制剂包含修饰释放元件，提供药物递送到受影响的或期望的区域。 可用本发明治疗的疾病和病症包括克罗恩病和溃疡性结肠炎。

    Multiparticulate modified release composition
    30.
    发明申请
    Multiparticulate modified release composition 审中-公开
    多微粒改性组合物

    公开(公告)号：US20060240105A1

    公开(公告)日：2006-10-26

    申请号：US11372857

    申请日：2006-03-10

    申请人： John Devane ,  Paul Stark ,  Niall Fanning ,  Gurvinder Rekhi ,  Scott Jenkins ,  Gary Liversidge

    发明人： John Devane ,  Paul Stark ,  Niall Fanning ,  Gurvinder Rekhi ,  Scott Jenkins ,  Gary Liversidge

    IPC分类号： A61K31/485 ,  A61K31/192 ,  A61K9/26

    CPC分类号： A61K31/485 ,  A61K9/501 ,  A61K9/5015 ,  A61K9/5026 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/192

    摘要： The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers at least one active ingredient in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles wherein the combination of the components exhibit a bimodal or multimodal release profile. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition.

    摘要翻译： 本发明涉及一种多微粒改性释放组合物，其在给予患者时以双峰或多峰方式递送至少一种活性成分。 多微粒改性组合物包含第一组分和至少一个后续组分; 所述第一组分包含含有颗粒的第一组活性成分和所述至少一种随后组分，所述至少一种后续组分包含含有颗粒的第二组活性成分，其中所述组分的组合表现出双峰或多峰释放曲线。 本发明还涉及含有这种多微粒改性释放组合物的固体口服剂型。